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mortality in end-stage kidney disease: a
systematic review of observational studies
Pedro Martins1,2, Elisa A. Marques1, Diogo V. Leal1, Aníbal Ferreira2,3,4, Kenneth R Wilund5 and João L. Viana1*
Abstract
Background: End-stage Kidney Disease patients have a high mortality and hospitalization risk. The association of
these outcomes with physical activity is described in the general population and in other chronic diseases.
However, few studies examining this association have been completed in end-stage Kidney Disease patients, raising
the need to systematically review the evidence on the association of physical activity with mortality and
hospitalization in this population.
Methods: Electronic databases (EBSCO, Scopus and Web of Science) and hand search were performed until March
2020 for observational studies reporting the association of physical activity with mortality or hospitalization in adult
end-stage Kidney Disease patients on renal replacement therapy (hemodialysis, peritoneal dialysis and kidney
transplant). Methodological quality of the included studies was assessed using the Quality in Prognosis Studies tool.
The review protocol was registered in PROSPERO (CRD42020155591).
Results: Eleven studies were included: six in hemodialysis, three in kidney transplant, and two in hemodialysis and
peritoneal dialysis patients. Physical activity was self-reported, except in one study that used accelerometers. All-
cause mortality was addressed in all studies and cardiovascular mortality in three studies. Nine studies reported a
significant reduction in all-cause mortality with increased levels of physical activity. Evidence of a dose-response
relationship was found. For cardiovascular mortality, a significant reduction was observed in two of the three
studies. Only one study investigated the association of physical activity with hospitalization.
Conclusions: Higher physical activity was associated with reduced mortality in end-stage Kidney Disease patients.
Future studies using objective physical activity measures could strengthen these findings. The association of
physical activity with hospitalization should be explored in future investigations.
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Background
Progression of chronic kidney disease (CKD) is a major
concern as survival of end-stage kidney disease (ESKD)
patients depends on renal replacement therapy:
hemodialysis (HD), peritoneal dialysis (PD) or kidney
transplant (KT). Each year, about 440.000 patients
worldwide start renal replacement therapy [1], with HD
being the most common. However, KT is the most cost-
effective, promoting a better survival and quality of life
with reduced costs [2]. ESKD patients, particularly those
on HD and PD, have an increased mortality and
hospitalization [3], with these being important outcomes
that are a priority for patients, caregivers and healthcare
professionals [4, 5].
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Physical activity (PA), defined as any bodily move-
ment produced by the contraction of skeletal muscles
that increases energy expenditure above basal levels [6],
is associated with a reduced mortality in the general
population [7]. However, a relationship between PA
and mortality in ESKD has not been thoroughly estab-
lished. ESKD patients have a high prevalence of trad-
itional cardiovascular (CV) risk factors, as well as non-
traditional CV risk factors, such as microalbuminuria,
anaemia, oxidative stress, inflammation and hyperpho-
sphatemia [8]. Moreover, this population has an in-
creased risk for other specific causes of death (e.g.
infection) [9]. Thus, findings related to PA and mortal-
ity in the general population cannot be extrapolated to
CKD patients [10]. Several factors contribute to a vi-
cious cycle of reduced PA in ESKD: behavioural (e.g.
depression), pathophysiological (e.g. anaemia, HD-
related fatigue) and logistical (e.g. time spent on dialy-
sis) [11]. Therefore, inactivity (an insufficient PA level
to meet the World Health Organization recommenda-
tions [6]) is common in ESKD patients and is associated
with important predictors of mortality, such as inflam-
mation, body composition, physical function and car-
diorespiratory fitness [11]. A systematic review found
an inverse association between PA and mortality in
CKD [12]. However, this study was restricted to non-
dialysis patients, which have lower mortality and
hospitalization rates compared to ESKD patients [3].
No previous systematic reviews combined the evidence
on the association of PA with mortality and
hospitalization in the high-risk ESKD population.
This systematic review aims to examine whether
higher PA levels are associated with lower mortality and
hospitalization in adult patients with ESKD on renal re-
placement therapy. Our summarized evidence should
impact the kidney care community by raising awareness




The protocol of this study was registered on the Inter-
national Prospective Register of Systematic Reviews
(PROSPERO) (CRD42020155591) and can be assessed at
https://www.crd.york.ac.uk/PROSPERO/. This report
followed the recommendations of the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses
guidelines [13].
Criteria for considering studies for this review
The inclusion criteria for this review were: (1) observa-
tional studies; (2) reported associations between PA as
an exposure variable with all-cause or CV mortality and/
or hospitalization; (3) reported effect estimates with 95 %
confidence intervals (CI); and (4) adult (age ≥ 18 years
old) community-dwelling renal replacement therapy pa-
tients. Abstracts, conference papers and studies pub-
lished in non-English-language journals were excluded.
An inclusive approach was used regarding PA mea-
sures. Thus, any of the following were considered: (1)
any type of PA measurement, including self-reports, de-
vices and direct observation; (2) any of the PA dimen-
sions: frequency, intensity, time and type [14]; (3) any
PA domain: leisure-time, occupational, household and
transport-related [15]; (4) PA instruments reporting en-
ergy expenditure, and (5) summarized PA-related mea-
sures by devices (e.g. number of steps) [16].
Physical fitness and PA are two different constructs
[17]. Thus, studies using physical fitness measures and
reporting them as PA were excluded.
Search strategy for identification of studies
The EBSCO, Scopus, and Web of Science electronic da-
tabases were searched from their date of establishment
to 16 of March 2020. Text words used were: (exercise
OR “physical activity”) AND (mortality OR hospital* OR
“length of stay” OR “cardiovascular event”) AND
(“Chronic Kidney Insufficiency” OR “Chronic Kidney
Diseases” OR “Chronic Renal Diseases” OR “Chronic
Renal Insufficiency” OR “Renal dialysis” OR
“Hemodialysis” OR “HD” OR “Haemodialysis” OR “Kid-
ney Transplantation” OR “Renal Transplantation” OR
“Kidney Grafting”).
An additional hand search was performed to screen for
other potential eligible studies including the reference lists
from the included studies. Citations were managed using
the software EndNote X7.3.1 (Clarivate Analytics, USA).
The search strategy was conducted by one reviewer (PM).
An example of a full electronic search strategy (EBSCO)
can be found in additional file 1.
Data extraction and quality assessment
Results from the overall electronic search were
reviewed by two authors (PM and EAM) based on the
title and abstract. Articles deemed potentially relevant
were retrieved for full-text review and inspected to
avoid multiple publication bias. In cases of suspected
duplication, corresponding authors were contacted and,
if confirmed, preference was given to the studies with a
longer follow-up. Any disagreements were resolved via
joint consensus.
A data extraction form was used to capture relevant
information from the included studies. The following in-
formation was recorded: authors’ name, publication year,
country, follow-up length, sample size, type of renal re-
placement therapy, participants’ mean age, sex distribu-
tion, PA measurement, PA domains, PA output,
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outcome measures, adjustment variables, technique for
handling the missing data, and overall main findings.
The exposure variable was PA and outcomes of interest
were all-cause, CV or cause-specific mortality/
hospitalization. Measures of association were reported in
reference to the least physically active group. When
needed, authors were contacted to provide the missing
data.
The methodological quality of the studies was
evaluated using the Quality in Prognosis Studies
(QUIPS) tool [18]. This instrument includes six do-
mains: study participation, study attrition, prognos-
tic factor measurement, outcome measurement,
study confounding, and statistical analysis and
reporting. The original classification grades each
domain in three categories (high, moderate or low
risk of bias). We added an additional “unclear” cat-
egory that should be applied when a judgement is
not possible due to insufficient information. This
modified QUIPS tool is described in additional file
2. Two authors (PM and EAM) assessed the risk of
bias of all included studies. Discrepancies in scoring
were settled by agreement.
Results
Search results
Electronic search retrieved 2766 records and one add-
itional study was added through hand search [19]. After
removing duplicates (n = 725), 2042 titles were screened.
Whenever needed, abstracts were also analysed. Of the 48
full-text articles screened, eleven fulfilled the eligibility cri-
teria and were included. The flow diagram of the study se-
lection process is presented in Fig. 1, and the PRISMA
checklist is presented in the additional file 3.
Study characteristics
The characteristics of the included studies are summa-
rized in Table 1. Four studies were from USA [22, 25,
26, 29], two from Europe [19, 28], two from Asia [23,
24] and one from Canada [27]. Two studies pooled data
from several countries [20, 21]. The number of partici-
pants ranged from 109 patients [27] to 20920 patients
Fig. 1 Flowchart of studies selection. PA physical activity; CKD chronic kidney disease
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[20], and mean age from 48 [29] to 65 years [24]. Six
studies were in HD [20–25], three in KT [19, 28, 29],
and two in HD and PD patients [26, 27]. None of the
studies addressed PD patients alone. The mean/median
length of follow-up ranged from 1.5 years [23] to 8.4
years [29]. In eight studies PA was measured using a val-
idated self-report questionnaire [19, 21–23, 25, 27–29],
two used a single question on exercise frequency [20,
26], and one study used accelerometry [24]. All the re-
ports measured, at least, the leisure-time PA domain;
one study also included the transport-related PA [19];
and three studies reported an overall score that com-
bined all PA domains [21, 24, 28]. Zhang et al. [23] and
Byambasukh et al. [19] reported outcomes in relation to
specific PA intensities, namely light PA and moderate to
vigorous PA, respectively.
Table 1 Characteristics of the included studies


















HD; n = 20,920;




Leisure time Categorical: never or < 1 time/wk; 1 time/wk; 2–3
times/wk; 4–5 times/wk; 6–7 times/wk (daily)
Dichotomous: ‘regular exercise’











HD; n = 5763;
63.4 ± 14.5; 38.3
1.6 Self-reported:
RAPA
Total Categorical: Never/rarely active (rarely or never do
any PA); infrequently active (some light or moderate
PA, not every wk); sometimes active (light PA, every
wk); often active (moderate PA: < 30 min, 5 days/wk
or vigorous PA: < 20 min, 3 days/wk); very active
(moderate PA: > 30 min, 5days/wk or vigorous PA:





HD, n = 755;











HD; n = 317;








Continuous: each point increase in light PA time






HD; n = 282;
64.8 ± 10.6; 45.0
4.7 Device:
Accelerometer
Total Dichotomous: <4000 steps/non-HD day or ≥ 4000
steps/non-HD day






HD; n = 727;






Dichotomous: Inactive (< 383 kcal/wk; women, <






HD/PD; n = 2386;











Brar et al. 2019;
Canada [27]







Dichotomous: Inactive (men: <383 kcal/wk;
women: <270 kcal/wk) or Active (men: ≥383 kcal/
wk; women: ≥270 kcal/wk)
All-cause
mortality














KT; n = 507;











et al. 2020; The
Netherlands
[19]








Categorical: inactive (no MVPA); less active (median




Age is presented as mean ± standard deviation; 1Australia, Belgium, Canada, France, Germany, Italy, Japan, New Zealand, Spain, Sweden, UK, USA; 2Pooled mean
based on the mean age reported for each group; 3median values are reported, otherwise mean values are presented as listed; 4Cutoffs not reported; 5Authors
intentionally excluded occupational of the total reported PA measure
HD hemodialysis; RAPA Rapid Assessment of physical activity; PA physical activity; MLTAQMinnesota Leisure Time Activity Questionnaire; PARQ Physical Activity
Recall Questionnaire; PD peritoneal dialysis; CV cardiovascular; PASE Physical Activity Scale for the Elderly; KT kidney transplant; TOAQ Tecumseh Occupational
Activity Questionnaire; SQUASH Short questionnaire to assess health-enhancing physical activity; MVPAmoderate-to-vigorous PA
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All studies investigated the association of PA with all-
cause mortality and, of those, three studies also investi-
gated CV mortality [19, 26, 28]. No studies were found
for other specific causes of mortality. The association be-
tween PA and hospitalization was explored in one study
only [20].
Risk of bias
Risk of bias was evaluated using the QUIPS tool (see
Table 2). Across-studies, most domains showed low risk
of bias. Thus, results were unlikely altered by methodo-
logical flaws. However, due to poor reporting of loss to
follow up, the ‘study attrition’ domain was categorized as
unclear in most studies. Potential bias in ‘prognostic fac-
tor measurement’ was related with the simplistic assess-
ment of PA, mostly capturing only the frequency
component [20, 26].
Physical Activity and Mortality outcomes
Overall, the results showed that higher PA was associ-
ated with reduced mortality rates. Heterogeneity among
the studies (statistically, clinically, and methodologically)
precluded quantitative synthesis (meta-analysis). Hazard
ratio (HR) or relative risk were reported in all studies
(summarized in Table 3). For all-cause mortality, the as-
sociation was statistically significant in nine studies [19–
25, 28, 29]. Comparing the lowest and the highest phys-
ically active groups, HR ranged from 0.42 [95% CI: 0.22-
0.82] [24] to 0.70 [95% CI: 0.53-0.93] [25] (Fig. 2). These
results were independent of the exposure measure, levels
for PA categorization, and adjustment for confounders.
Thus, studies in HD [20–25] and KT [19, 28, 29] all sup-
ported a significant inverse association between PA and
all-cause mortality. The two studies that included pa-
tients under HD or PD [26, 27] reported no evidence of
significant association between mortality and PA [27], or
no association only in the group of patients exercising
more than 2-3 times/week [26].
Based on frequency alone [20, 26] or combining fre-
quency, duration, and intensity [19, 21, 29], five studies
grouped patients in three or more PA levels, allowing
for a dose-response analysis. In four of these studies, a
graduated dose-response was observed [19–21, 29]. The
exception was Stack and colleagues [26] study in which
the protective benefit of PA was reduced for patients ex-
ercising more than 2–3 times/week.
All studies exploring PA as a continuous variable,
demonstrated that PA increments (one hour/week of
light PA [23], 1000 steps/non-HD day [24], 1 MET-min/
day [28], or 10-unit increase in PASE score [29]) have an
inverse significant association with all-cause mortality
[23, 24, 28, 29].
The association of PA with CV mortality was ad-
dressed in three studies [19, 26, 28]. Of those, two stud-
ies found an inverse significant association between PA
and CV mortality with a similar magnitude to results re-
ported for all-cause mortality [19, 28]. The other study
found no evidence of association between PA and CV
mortality [26].
Physical Activity and Hospitalization outcomes
This review includes only one study addressing the asso-
ciation between PA and the hospitalization risk [20],
which reported that patients exercising ≥ 1time/week,
compared to patients exercising < 1time/week, had a
similar risk of hospitalization for all-cause (HR = 1.00
[95 % CI: 0.96–1.04]), cardiac events (HR = 0.97 [95 %
CI: 0.91–1.03]), and amputations (HR = 0.98, [95 % CI:
0.83–1.17]). Also, patients exercising ≥ 1time/week had a
significant lower fracture-related hospitalization risk
(HR = 0.76 [95 % CI: 0.61–0.94]).













Tentori et al. 2010 [20] Low Low High Low Low Low
Lopes et al., 2014 [21] Low Unclear Low Low Low Low
Kutner et al., 2016 [22] Low Unclear Low Low Low Low
Zhang et al., 2017 [23] Moderate Low Low Low Moderate Low
Matsuzawa et al., 2018 [24] Moderate Unclear Low Low Low Low
Johansen et al., 2019 [25] Low Unclear Low Low Low Low
Stack et al., 2005 [26] Moderate Low High Low Low Low
Brar et al., 2019 [27] Moderate Low Low Low Low Low
Zelle et al., 2011 [28] Low Unclear Low Low Low Low
Rosas et al., 2012 [29] Low Unclear Moderate Low Low Low
Byambasukh et al., 2020 [19] Low Low Low Low Low Low
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Table 3 Summary of findings: association of PA and mortality outcomes











HD Age, sex, black (Y/N), ESRD duration, BMI,
14 comorbid conditions (Y/N)2, albumin,
phosphorus, calcium, creatinine, Hgb,
catheter use (Y/N), smoker (Y/N), some
college education (Y/N), employed (Y/N),
private insurance (Y/N), lives alone (Y/N)
and able to walk (Y/N)
All-cause mortality risk ↓ with ↑
PA (exercise frequency)














(n = 3558): 0.72
[0.66–0.79]
4–5 times/wk
(n = 1201): 0.73
[0.62–0.86]
6–7 times/wk




Region3, age, sex, black (Y/N), smoker (Y/
N), employed (Y/N), some college
education (Y/N), lives alone (Y/N),
assistance with walking (Y/N), time on
HD, strength/flexibility activities (Y/N), BMI,
14 comorbid conditions2, catheter use (Y/
N), Hgb, Kt/V, creatinine, albumin, calcium,
systolic BP < 120mmHg (Y/N), systolic
BP > 160mmHg (Y/N) phosphorus, PTH
and nPCR

















active (n = 1649)
Infrequently
active (n = 599):
0.89 [0.72–1.10]
Sometimes
active (n = 969):
0.84 [0.67–1.05]
Often active
(n = 1373): 0.81
[0.68–0.96]





Age, sex, race (White, Black, other),
college education (Y/N), current smoker
(Y/N), participant clinic, BMI, diabetes (Y/
N), CV comorbidity (Y/N)4, lupus/
rheumatoid arthritis (Y/N), COPD (Y/N),
cancer (Y/N), ESRD duration, catheter use
(Y/N), hours wk/HD treatment














Age All-cause mortality risk ↓ with ↑
light and overall PA












Age, sex, time on HD, BMI, diabetes (Y/N),
peripheral vascular disease (Y/N), CBV
accident/transient ischemic attack (Y/N),
geriatric nutritional risk index, and
comorbidity score
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Table 3 Summary of findings: association of PA and mortality outcomes (Continued)













Age, sex, race (Black, White, Asian, other),
Hispanic (Y/N), BMI, time on HD, diabetes
(Y/N), atherosclerotic heart disease (Y/N),
heart failure (Y/N), catheter use (Y/N),
albumin
All-cause mortality risk is related
with all frailty components












Age, sex, race (White, Black, Asian), cause
of ESRD (glomerulonephritis, diabetes,
hypertension), congestive heart failure (Y/
N), coronary artery disease (Y/N),
peripheral vascular disease (Y/N), left
ventricular hypertrophy (Y/N),
undernourished (Y/N, caregiver subjective
opinion), albumin, phosphorus and
hematocrit
All-cause mortality risk ↓ for
patients exercising 2–3 times/wk.
No significant results for 4–5
times/wk and daily exercise.






(n = 437): 0.74
[0.58–0.95]
4-5times/wk
(n = 134): 0.70
[0.47–1.04]









Age, sex, albumin, hemoglobin and
number of comorbidities
No significant reduction in all-








KT Age, sex, history of CV events5 (Y/N),
insulin concentration, systolic BP, waist
circumference, triglycerides, smoker (Y/N),
CRP, Framingham risk score, creatinine
clearance, urinary protein excretion, 24-h
urinary creatinine
All-cause and CV mortality risk ↓
with ↑PA










Recipient and donor age, African
American (Y/N), sex, diabetes (Y/N),
dialysis duration, ever smoked (Y/N), BMI,
delayed graft function6 (Y/N)
All-cause mortality risk ↓ with
























Age, sex, eGFR, urinary protein excretion,
time between transplantation and
baseline, primary renal disease7, acute
rejection (Y/N), pre-emptive transplant-
ation (Y/N), living donor (Y/N), current
smoker (Y/N), total alcohol consumption,
total energy intake, immunosuppressive
medication (Y/N) 8, systolic BP, use of anti-
hypertensive drugs (Y/N), triglycerides,
HDL-C, BMI, waist circumference, 24-h cre-
atinine excretion





Less active (n =
201): 0.45
[0.29–0.70]










1Data not reported for other PA categories: 4-5times/wk and daily PA (results were not significant); 2diabetes, hypertension, coronary artery disease, congestive
heart failure, other cardiovascular disease, peripheral vascular disease, cerebrovascular disease, recurrent cellulitis, GI bleed, lung disease, neurologic disorder,
depression, other psychiatric disorders, cancer other than skin, HIV; 3Europe, Australia/New Zealand, Japan or North America; 4congestive heart failure, coronary
artery disease, cerebrovascular accident, peripheral vascular disease, other cardiac diseases; 5myocardial infarction or transient ischemic attack/CBV accident; 6need
for dialysis during the 1st week after transplantation; 7glomerulosclerosis, glomerulonephritis, tubulointerstitial nephritis, polycystic kidney disease, renal
hypodysplasia, renavascular diseases, diabetes, others; 8calcineurin inhibitors, prednisolone; 9data not provided for each PA group
HR hazard ratio; RR relative risk; CI confidence interval; CV cardiovascular; ESRD end-stage renal disease; BMI body mass index; BP blood pressure; PTH parathyroid
hormone; nPCR normalized protein catabolic rate; PA physical activity; COPD chronic obstructive pulmonary disease; HD hemodialysis; CBV cerebrovascular; CRP C-
reactive protein; METmetabolic equivalents
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Discussion
Summary of main findings
This systematic review found evidence of a significant
and consistent association between higher PA levels and
reduced mortality in ESKD patients. This finding is sus-
tained by studies addressing all-cause mortality. Results
are less robust for CV mortality as this outcome was
only addressed in three studies [19, 26, 28]. The associ-
ation between PA and hospitalization was only reported
in one study [20], therefore no conclusions can be
drawn. Nevertheless, this study demonstrated that phys-
ically active patients have a lower hospitalization risk
due to fractures [20].
Results for HD and KT patients are consistent in
favour of a protective effect of PA on all-cause mortality.
PD patients were only investigated in combination with
HD patients, and results are somewhat conflicting [26,
27]. Brar et al. [27] found a non-significant reduction in
all-cause mortality. However, this is the study with the
smallest sample (n = 109), possibly underpowered to find
a significant association. Stack et al. [26] observed a sig-
nificant lower mortality risk for patients exercising 2–3
times/week. However, unexpectedly, this benefit was re-
duced for patients exercising more than 2–3 times/week.
Nevertheless, the large proportion of patients in the
higher exercise frequency groups (e.g. 20.2 % of patients
exercising daily) seems unrealistic for dialysis patients
and it is indicative of some potential bias (e.g. physio-
therapy) that might have led to this intriguing result.
These discrepant findings suggest more research is
needed, preferably with more accurate PA measures, to
evaluate the dose-response association between PA and
mortality.
In line with findings for the general population [7], we
observed a dose-response association between PA and
all-cause mortality, demonstrated in studies with three
or more PA volume categories [19–21, 29], with the ex-
ception of the study from Stack et al. [26]. The evidence
of a dose-response association is a relevant finding, espe-
cially for deconditioned ESKD patients since the benefits
of PA were observed even with modest PA amounts.
Some methodological drawbacks can be caused by the
categorization of continuous variables, particularly if
data-dependent quantiles are used to form categories.
Therefore, more robust findings are obtained when the
exposure is analysed as a continuous variable [30]. In the
present review, four studies reported results based on
continuous PA data and found reductions in all-cause
mortality with increments in PA [23, 24, 28, 29]. These
results strengthen the evidence of an inverse association
between PA and all-cause mortality in ESKD.
The association of PA with CV mortality is paramount
as CV complications are the main cause of death in
ESKD [1]. Although only three studies addressed this
outcome [19, 26, 28], two of them found a protective
role of PA that was similar for all-cause and CV mortal-
ity. This finding is in agreement to those for the general
population [31]. Because in ESKD, non-CV and CV
mortality share common risk factors, such as infections
and inflammation [32], it is impossible to differentiate
the mechanisms exclusively affecting CV from those
supporting non-CV mortality. Nevertheless, several
mechanisms related to PA may decrease CV mortality in
ESKD. Specifically, it is known that an increase in PA
may reduce the progression of atherosclerosis and even
reduce the atherosclerotic burden [33], it improves
endothelial function by increasing the laminar sheer
stress rising nitric oxide bioavailability [34], and reduces
arterial stiffness by improving vasodilation due to ele-
vated nitric oxide levels and preventing the connective
tissue building-up in the arteries [33]. PA may also exert
anti-inflammatory effects [35], and has been observed to
be associated with reduced oxidative stress (i.e. increase
in antioxidants resulting in less accumulation of reactive
oxygen species) [33]. Furthermore, higher PA levels im-
prove CV risk profile (blood pressure control and blood
Fig. 2 Results of the included studies comparing all-cause mortality in most active and inactive groups
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lipid profile) [33], with anti-ischemic effects of PA being
potentially related to an enhanced coronary blood flow
reserve [33]. On the other hand, PA may activate anti-
arrhythmic protective mechanisms due to a reduction in
sympathetic and increase in parasympathetic/vagal
stimulation of the myocardium, improving the electrical
stability of the heart [33]. PA has also been observed to
elicit antithrombotic effects creating an environment
that favours fibrinolysis over thrombosis [33]. All these
mechanisms may explain the reduced CV mortality in
active patients. The prevention of muscle wasting and
functional decline, important predictors of mortality in
ESKD, may also explain why PA decreases all-cause
mortality in this population [11].
This review provided empirical evidence that PA is as-
sociated with a reduced mortality risk in this population.
Because renal replacement therapies are fundamentally
used to sustain life, strategies that improve survival
should be combined with this treatment. Thus, interven-
tions to promote PA should be implemented in clinical
settings.
Strengths and limitations
Regarding the type of renal replacement therapy, none
of the included studies provided data on PD patients
alone, which limited our conclusions for this specific
population.
Evidence shows that self-reported measures tend to
underestimate the association between PA and mortality
[31]. This is possibly explained by their overestimation
of PA [14]. If so, we might have underestimated the pro-
tective role of PA. Also, some studies only assessed
leisure-time PA, which fails to capture the overall PA
behaviour. However, the resulting bias may have been
minimal as this is the predominant PA domain in devel-
oped countries [36].
Another potential bias is related to the observed
underreported study attrition. Thus, there may be un-
known reasons for loss to follow-up that could have in-
fluenced the outcomes (e.g., discontinuation of HD
treatment can precede mortality).
Additionally, reverse causality may have overestimated
our results. Usually, most ill patients have reduced PA
levels. Thus, the observed association between PA and
mortality could also have been driven by the poor health
status, rather than the PA exposure per se [37]. Some of
the included studies have a short follow-up period and
are, consequently, at an increased risk of reverse causal-
ity. Nevertheless, most studies performed an analysis ad-
justed for baseline comorbidities that may have
minimized this bias.
Finally, confounding bias could have also influenced
our results. Nevertheless, most studies performed a com-
prehensive adjusted analysis. Even so, we cannot rule
out a residual confounding from non-controlled
variables.
Agreements and disagreements with other studies and
reviews
The influence of PA on hard clinical endpoints (e.g.
mortality) was already demonstrated in previous system-
atic reviews in the general population [7], and in patients
with diabetes [38], which is commonly observed in
ESKD patients. There are comparable findings to the
present review. Firstly, the dose-response association be-
tween PA and all-cause mortality is supported by other
reviews [7, 38]. Secondly, when inactive patients were
compared with the most active patients, our observed
risk reduction for all-cause mortality ranged from 30 %
[25] to 58 % [24], which is comparable to that observed
for diabetic patients in the same activity-pattern groups
(i.e. inactive versus active patients) (40 %) [38]. Also, evi-
dence suggests that PA may equally decrease mortality
in healthy and in chronic disease patients [39]. However,
a higher protective effect of PA (73 % reduction in all-
cause mortality) has been reported for the general popu-
lation [7] compared with our findings. That review only
included accelerometer-based studies, which may ex-
plain the differences in the reported HR.
The mineral and bone disorders of CKD causes bone
fragility resulting in a higher risk of fractures and, conse-
quently, an increase in hospitalization and mortality
rates [40]. Thus, strategies to reduce bone fractures in
this population are needed. PA should be considered as
a key element in these strategies, as it acts favourably in
two key risk factors: bone characteristics (such as min-
eral density) [41] and the prevention of falls [42]. Despite
in this systematic review only one study investigated the
association between PA and hospitalization, a potential
for a reduction in fracture-related hospitalizations is as-
sumed [20]. This result agrees with the findings from a
previous umbrella review in older adults [43].
Conclusions
The present systematic review finds evidence of a dose-
response reduction in all-cause mortality associated with
increased PA. Moreover, greater PA was associated with
a reduction in CV mortality; however, the lack of studies
exploring the link between PA and CV mortality, as well
as hospitalization, limited the strength of our
conclusions.
Implications for practice and future research
Despite the well-accepted wide-range health benefits at-
tributed to PA, there is still a lack of efficient strategies
in renal care targeting the low levels of PA in these pa-
tients [44], which may be in part because PA is a com-
plex behaviour and its promotion is a challenge in
Martins et al. BMC Nephrology          (2021) 22:227 Page 9 of 11
healthcare settings [45]. Thus, to successfully change PA
behaviour, approaches must be grounded in relevant
theories and target both, the individual and their envir-
onment [46]. Such a comprehensive intervention is not
common in ESKD patients, but is popular in pulmonary
[47] and cardiac rehabilitation [48]. Nevertheless, some
successful approaches of sustainable exercise programs
are also known for ESKD patients, including intradialytic
exercise, home-based exercise, inter-dialytic exercise,
prehabilitation for transplant candidates, rehabilitation
post-transplant and education programs [49]. The
present findings should inform policy makers and other
stakeholders for the need to address inactivity in this
population.
We identified several issues that must be a priority in
future studies design, specifically (1) targeting all differ-
ent renal replacement therapy (particularly PD patients),
(2) collecting data on the specific causes of mortality
(e.g., CV, infection, or cancer) and in hospitalization out-
comes, and (3) using accelerometry to objectively meas-
ure PA. This would provide more reliable PA data and
the opportunity to explore the role of each PA compo-
nents (frequency, intensity, and duration), and sedentary
behaviour. Moreover, collecting PA data at different
timepoints could inform the clinical significance of PA
variations over time.
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